Table 3.

AKI in patients administered L-AMB.

Occurrence of AKI	Cases (%) (N = 507)
AKI
Total	189 (37%)
Cr ≥ 1.5-fold within 7 days	175 (35%)
∆Cr ≥ 0.3 mg/dL within 2 days	97 (19%)
AKI stage
Stage 1 (Cr ≥ 1.5 to < twofold or ∆Cr ≥ 0.3 mg/dL)	100 (20%)
Stage 2 (Cr ≥ 2 to < threefold)	55 (11%)
Stage 3 (Cr ≥ threefold or Cr ≥ 4.0 mg/dL or dialysis)	34 (7%)
Dialysis	2 (0%)

Period from L-AMB therapy initiation to AKI	Days
All patients	9.3 ± 10.4 (189 cases)
Patients with AKI except for dialysis	9.2 ± 10.4 (187 cases)
Patients with dialysis
Time to Cr ≥ 1.5 or ∆Cr ≥ 0.3 mg/dL	18.0 ± 1.0 (2 cases)
Time to dialysis	20.0 ± 0.0 (2 cases)

AKI acute kidney injury, L-AMB liposomal amphotericin B.